SecBot SecBot
SECBOTREPLAY Home › Report › ANVS

ANVS · Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared…

Annovis Bio Inc. · PRESS-RELEASE filed Mar 19, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 19, 2026 at 07:30 ET

Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoing open-label Parkinson’s disease trial (ANVS-25002). The technology enables real-time, passive monitoring of core PD symptoms using wearables, complementing biological biomarker data from skin-based alpha-synuclein testing to enhance trial precision and real-world evidence collection.

  • Annovis Bio partnered with NeuroRPM to use its FDA-cleared AI platform for real-time monitoring of Parkinson’s symptoms (bradykinesia, tremor, dyskinesia) in the ANVS-25002 open-label study.
  • The study is enrolling 500 patients; 90 have been enrolled so far.
  • NeuroRPM’s platform uses wearable sensors for passive, continuous data collection in real-world settings.
  • Annovis is also using a biomarker test for misfolded phosphorylated alpha-synuclein with >90% sensitivity and specificity.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access